Table 1.
Demographic and clinical data of anti-CCP positive and negative RA patients.
| Parameter | Anti-CCP positive RA (n = 40) | Anti-CCP negative RA (n = 40) | P value |
|---|---|---|---|
| Female patients | 34 (85%) | 38 (95%) | 0.136 |
| Age (years) | 39 ± 10.6 | 41.35 ± 8.24 | 0.272 |
| Disease duration (years) | 6.24 ± 3.76 | 4.18 ± 2.05 | 0.003* |
| Early morning stiffness (h) | 1.18 ± 0.98 | 0.60 ± 0.72 | 0.004* |
| Menstrual history (Normal/Menopause) | 21/13 | 20/18 | 0.243 |
| OCP use | 5 (12.5%) | 0 (0%) | 0.021* |
| Deformity (yes/no) | 7 (17.5) | 2 (5%) | 0.077 |
| BMI (Kg/m2) | 21.27 ± 2.35 | 22.74 ± 2.28 | 0.06 |
| Body surface area (m2) | 1.47 ± 0.14 | 1.47 ± 0.12 | 0.886 |
| Systolic BP (mm of Hg) | 127.65 ± 7.21 | 128.3 ± 6.21 | 0.667 |
| Diastolic BP (mm of Hg) | 79.3 ± 4.97 | 78.95 ± 5.24 | 0.760 |
| Steroid use (years) | 0.51 ± 0.76 | 2.4 ± 1.59 | <0.001* |
| Methotrexate use (years) | 1.05 ± 1.76 | 2.13 ± 1.68 | 0.006* |
| Sulphasalazine use (years) | 1.02 ± 1.77 | 1.6 ± 1.59 | 0.128 |
| Hydroxychloroquin use (years) | 0.7 ± 1.01 | 0.2 ± 0.52 | 0.007* |
| Leflunamide use (years) | 0.03 ± 0.16 | 0.00 ± 0.00 | 0.226 |
| Tender joint count | 12.38 ± 7.07 | 5.45 ± 5.79 | <0.001* |
| Swollen joint count | 8.73 ± 6.72 | 4.3 ± 5.25 | 0.002* |
*P value was statistically significant. Anti-CCP – Anti-cyclic citrullinated peptide; RA – Rheumatoid arthritis; OCP – Oral contraceptive pill; BMI – Body mass index; BP – Blood pressure.